HDL-Atherosclerosis Treatment Study
The HDL-Atherosclerosis Treatment Study, also known as HATS, was a three-year double-blind trial involving 160 people with coronary heart disease (CHD) who had a low HDL and near normal LDL. The study compared a combination of simvastatin and niacin with antioxidant vitamin therapy. Using angiography, coronary artery stenosis progressed when using placebo or antioxidant alone, and regressed with the combination of simvastatin and niacin. The study demonstrated a 90% reduction in CHD death, nonfatal heart attacks, stroke, or revascularization for worsening angina. It was published in 2001.[1][2][3][4]
See also
[edit]References
[edit]- ^ "HDL-Atherosclerosis Treatment Study". American College of Cardiology. 9 May 2002. Retrieved 5 April 2020.
- ^ Codario, Ronald A. (2007). Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. Springer Science & Business Media. p. 162. ISBN 978-1-59259-932-5.
- ^ Brown, B. Greg; Zhao, Xue-Qiao; Chait, Alan; Fisher, Lloyd D.; Cheung, Marian C.; Morse, Josh S.; Dowdy, Alice A.; Marino, Emily K.; Bolson, Edward L.; Alaupovic, Petar; Frohlich, Jiri (2001). "Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease". New England Journal of Medicine. 345 (22): 1583–1592. doi:10.1056/NEJMoa011090. ISSN 0028-4793. PMID 11757504.
- ^ Prasad, Kedar N. (2016). Micronutrients in Health and Disease. CRC Press. pp. 62–64. ISBN 978-1-4398-2107-7.
 | This medical article is a stub. You can help Wikipedia by expanding it. |